Eton Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 9, 2024. Financial amounts below are in thousands of dollars unless otherwise noted. Eton develops and commercializes rare-disease treatments. It reported five commercial products and three late-stage candidates: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Financial results
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net revenue | $7,966 | $5,304 |
| Gross profit / gross margin | $5,007 / 62.9% | $3,346 / 63.1% |
| Research and development | $651 | $535 |
| General and administrative | $5,156 | $5,345 |
| Operating loss | $(800) | $(2,534) |
| Net loss | $(811) | $(2,660) |
| Net loss per share, basic and diluted | $(0.03) | $(0.10) |
| Net cash used in operating activities | $(2,473) | $(1,548) |
Revenue increased about 50%, primarily on higher ALKINDI SPRINKLE and Carglumic Acid sales. Gross profit rose about 50%, while gross margin was broadly stable. Operating and net losses narrowed as revenue growth and lower G&A more than offset higher R&D and cost of sales. R&D growth primarily reflected ET-400 development.
Cash and cash equivalents were $16,655 at March 31, 2024, versus $21,388 at December 31, 2023. Working capital was $9.0 million. Investing cash outflow was $1,882, mainly for PKU GOLIKE product rights; financing cash outflow was $378, including $385 of debt repayment. The company had $5,020 of net debt, classified as current, and reported $5,905 of remaining-2024 SWK loan principal and interest payments.
Changes, outlook, and risks
- In March 2024, Eton acquired PKU GOLIKE rights for $2,350, allocated between $482 of inventory and $1,868 of intangible assets. The agreement includes potential commercial milestones up to $2,000 and a 30% royalty on net sales.
- Management believes cash and revenue from approved products will fund operating and capital needs for at least 12 months from filing. This depends on sales, spending, and other assumptions; the company cautions that it may need additional capital and cannot assure financing will be available on acceptable terms.
- Revenue and receivables are highly concentrated: AnovoRx accounted for 97.7% of Q1 2024 net revenue and 94.8% of March 31 net receivables. Eton also relies on a small number of third-party suppliers.
- The SWK loan is secured, subject to covenants, and its remaining balance is due in 2024. Product development, regulatory approvals, sales growth, financing availability, and estimates for returns, rebates, and chargebacks are key uncertainties.
- The filing reports no pending or threatened litigation expected to materially affect operations and no material subsequent events. Management concluded disclosure controls were effective; no material internal-control changes were reported. No specific financial guidance was provided.
Important facts for investors to verify
- Whether sales growth—especially in ALKINDI SPRINKLE and Carglumic Acid—continues, and how much revenue remains concentrated in AnovoRx.
- Cash burn and working-capital needs, including inventory growth and the timing and amount of SWK debt repayment.
- PKU GOLIKE launch contribution, margins, royalties, and any milestone payments, alongside progress and spending on ET-400, ET-600, and ZENEO.
- Reliance on key manufacturers and distributors, and the effect of product returns, chargebacks, rebates, and other revenue reserves.
- Whether management’s stated 12-month liquidity outlook remains achievable under actual sales and spending; the filing warns additional financing may be needed if assumptions change.